Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

Wierda WG, Dorritie KA, Gauthier J, Nath R, Kipps TJ, Riedell PA, Eradat HA, Kenderian SS, Kharfan-Dabaja MA, Shah NN, Solomon SR, Stephens DM, Ermann DA, Arnason JE, Deol A, Feldman TA, Andreadis CB, Ghosh M, Ma S, Schuster SJ, Gergis U, Vose JM, Soumerai JD, van Besien K, Tuazon SA, Perna SK, Ou SS, Ananthakrishnan R, Rane N, Papp E, Ansari S, Thompson EG, Okal A, Peiser L, Chen Y, Sengupta S, Ray PR, Wang J, Siddiqi T.

Open source

DOI: 10.1182/blood.2026033565
Published: 2026-07-28
Container: Blood
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2026033565,
  title = {Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.},
  author = {Wierda WG and  Dorritie KA and  Gauthier J and  Nath R and  Kipps TJ and  Riedell PA and  Eradat HA and  Kenderian SS and  Kharfan-Dabaja MA and  Shah NN and  Solomon SR and  Stephens DM and  Ermann DA and  Arnason JE and  Deol A and  Feldman TA and  Andreadis CB and  Ghosh M and  Ma S and  Schuster SJ and  Gergis U and  Vose JM and  Soumerai JD and  van Besien K and  Tuazon SA and  Perna SK and  Ou SS and  Ananthakrishnan R and  Rane N and  Papp E and  Ansari S and  Thompson EG and  Okal A and  Peiser L and  Chen Y and  Sengupta S and  Ray PR and  Wang J and  Siddiqi T.},
  year = {2026},
  journal = {Blood},
  doi = {10.1182/blood.2026033565},
  url = {https://doi.org/10.1182/blood.2026033565}
}

RIS

TY  - JOUR
TI  - Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.
AU  - Wierda WG
AU  -  Dorritie KA
AU  -  Gauthier J
AU  -  Nath R
AU  -  Kipps TJ
AU  -  Riedell PA
AU  -  Eradat HA
AU  -  Kenderian SS
AU  -  Kharfan-Dabaja MA
AU  -  Shah NN
AU  -  Solomon SR
AU  -  Stephens DM
AU  -  Ermann DA
AU  -  Arnason JE
AU  -  Deol A
AU  -  Feldman TA
AU  -  Andreadis CB
AU  -  Ghosh M
AU  -  Ma S
AU  -  Schuster SJ
AU  -  Gergis U
AU  -  Vose JM
AU  -  Soumerai JD
AU  -  van Besien K
AU  -  Tuazon SA
AU  -  Perna SK
AU  -  Ou SS
AU  -  Ananthakrishnan R
AU  -  Rane N
AU  -  Papp E
AU  -  Ansari S
AU  -  Thompson EG
AU  -  Okal A
AU  -  Peiser L
AU  -  Chen Y
AU  -  Sengupta S
AU  -  Ray PR
AU  -  Wang J
AU  -  Siddiqi T.
PY  - 2026
JO  - Blood
DO  - 10.1182/blood.2026033565
UR  - https://doi.org/10.1182/blood.2026033565
ER  -

APA

WG, W., KA, D., J, G., R, N., TJ, K., PA, R., HA, E., SS, K., MA, K., NN, S., SR, S., DM, S., DA, E., JE, A., A, D., TA, F., CB, A., M, G., S, M., SJ, S., U, G., JM, V., JD, S., K, V. B., SA, T., SK, P., SS, O., R, A., N, R., E, P., S, A., EG, T., A, O., L, P., Y, C., S, S., PR, R., J, W., & T., S. (2026). Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.. Blood. https://doi.org/10.1182/blood.2026033565

Source records

europe-pmc · retrieved 2026-09-25T19:28:03.974Z